BRISTOL-MYERS SQUIBB COMPANY Available-for-sale Securities, Gross Unrealized Losses (Deprecated 2013-01-31)
BRISTOL-MYERS SQUIBB COMPANY (BMY) had Available-for-sale Securities, Gross Unrealized Losses (Deprecated 2013-01-31) of $17.00 million as of 2013-06-30, per its 10-Q filed 2013-07-25.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLosses1 · last filed 2013-07-25
- 2013-06-30: Available-for-sale Securities, Gross Unrealized Losses (Deprecated 2013-01-31) $17.00M.
- 2013-03-31: Available-for-sale Securities, Gross Unrealized Losses (Deprecated 2013-01-31) $1.00M.
- 2012-12-31: Available-for-sale Securities, Gross Unrealized Losses (Deprecated 2013-01-31) $1.00M.
- 2012-09-30: Available-for-sale Securities, Gross Unrealized Losses (Deprecated 2013-01-31) $2.00M.
| Period end | Available-for-sale Securities, Gross Unrealized Losses (Deprecated 2013-01-31) |
|---|---|
| 2013-06-30 | $17.00M 10-Q · filed 2013-07-25 |
| 2013-03-31 | $1.00M 10-Q · filed 2013-04-25 |
| 2012-12-31 | $1.00M 10-Q · filed 2013-07-25 |
| 2012-09-30 | $2.00M 10-Q · filed 2012-10-24 |
| 2012-06-30 | $4.00M 10-Q · filed 2012-07-25 |
| 2012-03-31 | $7.00M 10-Q · filed 2012-04-26 |
| 2011-12-31 | $6.00M 10-K · filed 2013-02-15 |
| 2011-09-30 | $5.00M 10-Q · filed 2011-10-27 |
| 2011-06-30 | $3.00M 10-Q · filed 2011-07-28 |
| 2010-12-31 | $12.00M 10-K · filed 2012-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |